With its hemophilia A gene therapy poised to go through a pivotal program by the end of next year, BioMarin $BMRN is raising hopes for its success with a new batch of Phase I/II data for its valrox program (valoctocogene roxaparvovec/BMN 270).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,